vs
Side-by-side financial comparison of Globalstar, Inc. (GSAT) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $72.0M, roughly 1.2× Globalstar, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 17.6%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 12.9%).
Globalstar, Inc. is an American telecommunications company that operates a satellite constellation in low Earth orbit (LEO) for satellite phone, low-speed data transmission and Earth observation. The Globalstar second-generation constellation consists of 25 satellites.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
GSAT vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $72.0M | $86.8M |
| Net Profit | $-11.6M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | -0.5% | -84.7% |
| Net Margin | -16.1% | — |
| Revenue YoY | 17.6% | 17.7% |
| Net Profit YoY | 76.9% | — |
| EPS (diluted) | $-0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $72.0M | $86.8M | ||
| Q3 25 | $73.8M | $67.5M | ||
| Q2 25 | $67.1M | $60.0M | ||
| Q1 25 | $60.0M | $49.3M | ||
| Q4 24 | $61.2M | $73.7M | ||
| Q3 24 | $72.3M | $58.6M | ||
| Q2 24 | $60.4M | $31.1M | ||
| Q1 24 | $56.5M | $715.0K |
| Q4 25 | $-11.6M | — | ||
| Q3 25 | $1.1M | $-91.3M | ||
| Q2 25 | $19.2M | $-111.7M | ||
| Q1 25 | $-17.3M | $-116.2M | ||
| Q4 24 | $-50.2M | — | ||
| Q3 24 | $9.9M | $-83.5M | ||
| Q2 24 | $-9.7M | $-97.1M | ||
| Q1 24 | $-13.2M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | -0.5% | -84.7% | ||
| Q3 25 | 13.8% | -140.7% | ||
| Q2 25 | 9.2% | -189.8% | ||
| Q1 25 | -14.2% | -245.8% | ||
| Q4 24 | -6.9% | -117.5% | ||
| Q3 24 | 13.0% | -152.1% | ||
| Q2 24 | -2.4% | -327.6% | ||
| Q1 24 | -8.3% | -16464.6% |
| Q4 25 | -16.1% | — | ||
| Q3 25 | 1.5% | -135.3% | ||
| Q2 25 | 28.6% | -186.2% | ||
| Q1 25 | -28.9% | -235.5% | ||
| Q4 24 | -82.1% | — | ||
| Q3 24 | 13.7% | -142.7% | ||
| Q2 24 | -16.0% | -312.2% | ||
| Q1 24 | -23.4% | -15800.8% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.01 | — | ||
| Q2 25 | $0.13 | $-0.33 | ||
| Q1 25 | $-0.16 | $-0.36 | ||
| Q4 24 | $-0.57 | $-0.24 | ||
| Q3 24 | $0.00 | $-0.28 | ||
| Q2 24 | $-0.01 | $-0.34 | ||
| Q1 24 | $-0.01 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $447.5M | $297.0M |
| Total DebtLower is stronger | $483.8M | — |
| Stockholders' EquityBook value | $355.7M | $698.6M |
| Total Assets | $2.3B | $913.2M |
| Debt / EquityLower = less leverage | 1.36× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $447.5M | $297.0M | ||
| Q3 25 | $346.3M | $300.8M | ||
| Q2 25 | $308.2M | $301.2M | ||
| Q1 25 | $241.4M | $359.7M | ||
| Q4 24 | $391.2M | $323.8M | ||
| Q3 24 | $51.9M | $397.5M | ||
| Q2 24 | $64.3M | $412.5M | ||
| Q1 24 | $59.3M | $356.2M |
| Q4 25 | $483.8M | — | ||
| Q3 25 | $508.6M | — | ||
| Q2 25 | $491.5M | — | ||
| Q1 25 | $502.7M | — | ||
| Q4 24 | $511.4M | — | ||
| Q3 24 | $394.4M | — | ||
| Q2 24 | $393.1M | — | ||
| Q1 24 | $398.7M | — |
| Q4 25 | $355.7M | $698.6M | ||
| Q3 25 | $364.8M | $702.3M | ||
| Q2 25 | $360.9M | $698.5M | ||
| Q1 25 | $344.3M | $767.9M | ||
| Q4 24 | $358.9M | $710.4M | ||
| Q3 24 | $394.1M | $773.5M | ||
| Q2 24 | $383.0M | $768.5M | ||
| Q1 24 | $377.1M | $680.0M |
| Q4 25 | $2.3B | $913.2M | ||
| Q3 25 | $2.2B | $904.9M | ||
| Q2 25 | $1.9B | $907.4M | ||
| Q1 25 | $1.7B | $966.7M | ||
| Q4 24 | $1.7B | $910.4M | ||
| Q3 24 | $917.6M | $991.1M | ||
| Q2 24 | $926.2M | $964.3M | ||
| Q1 24 | $917.0M | $869.8M |
| Q4 25 | 1.36× | — | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 1.43× | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | 1.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.9M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $175.9M | $-52.6M | ||
| Q3 25 | $236.0M | $-78.7M | ||
| Q2 25 | $157.9M | $-67.4M | ||
| Q1 25 | $51.9M | $-103.7M | ||
| Q4 24 | $340.7M | $-73.3M | ||
| Q3 24 | $32.0M | $-59.0M | ||
| Q2 24 | $36.7M | $-98.4M | ||
| Q1 24 | $29.8M | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | 216.53× | — | ||
| Q2 25 | 8.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.23× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GSAT
| Services | $67.4M | 94% |
| Products | $4.6M | 6% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
